Trial demonstrates early AI-guided detection of heart disease in routine practice
Related Articles
Anumana Makes Educated Inferences in Heart Failure
Anumana was founded in 2021 as the culmination of a joint effort between the Mayo Clinic and nference, an early entrant to the field of machine learning for cardiology-focused clinical…{post_date: F d, Y}
Anumana Collaborates with Leading Global Health Care Company to Detect Heart Disease Using Artificial Intelligence
Biospace: Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has launched a multi-year strategic collaboration with Novartis Pharmaceuticals Corporation (“Novartis”) to deploy a series of artificial…{post_date: F d, Y}
Anumana Announces Issuance of New American Medical Association CPT® Category III Codes for Novel ECG AI Analysis of Cardiac Dysfunction
Ground-breaking codes will facilitate the use, adoption, and pathway for potential reimbursement of AI-enhanced ECG-based algorithms, including Anumana’s pipeline of AI- enhanced ECG-based algorithms{post_date: F d, Y}
Anumana’s ECG-AI® Algorithms Honored with 2024 MedTech Breakthrough Award for “Best New Technology Solution-Cardiology”
Anumana’s innovative AI algorithms recognized for their transformative potential in cardiology - the first of which is now commercially available{post_date: F d, Y}